Glycidaldehyde CASRN 765-34-4 | IRIS

IRIS

System	RfD (mg/kg-day)	Basis	PoD	Composite UF	Confidence
Endocrine, Urinary, Hematologic, Other	4 x 10 ^-4	Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects	NOAEL : 1.09 mg/kg-day	3000	Low

Weight of Evidence for Cancer (PDF) (15 pp, 121 K) Last Updated: 08/01/1991

WOE Characterization	Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)	Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)

Basis:

Based on no human data and an increased incidence of malignant tumors in rats and mice following subcutaneous injection of glycidaldehyde and of skin carcinomas following dermal application to mice. Glycidaldehyde shows mutagenic activity in many assay systems and is known to be highly reactive because of the epoxide and the aldehyde groups. A number of structurally related epoxide compounds are also carcinogenic in experimental animals, including the analogues glycidol and propylene oxide.
This may be a synopsis of the full weight-of-evidence narrative.

Not assessed under the IRIS Program.

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

Human Health Benchmarks for Pesticides (HHBP). This database provides human health benchmarks for pesticides that may be present in drinking water.
Office of Pesticide Programs Pesticide Chemical Search. This database provides links to health effects information and registration status for pesticides.
Chemistry Dashboard. This database provides information on chemical structures, experimental and predicted physicochemical, and toxicity data.

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.